The publisher explores Amgen’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (20 May 2020)
Model updates (4 March 2020)
Model updates (21 November 2019)
Model updates (5 November 2019)
Model updates (29 July 2019)
Snapshot
- Overview: PharmaVitae forecasts Amgen’s sales to grow out to 2029.
- Key themes: [1] Successful resolution of Enbrel litigation a major positive for Amgen, as patent protection secured into 2029 [2] Pipeline has a few potential blockbusters, with tezepelumab and AMG 510 [3] Acquisition of Otezla adds a substantial boost to revenue in both near and long term, adding over $3bn by 2023 [4] Acquisition of Amgen Astellas BioPharma and 20.5% equity stake in BeiGene significantly transforms Amgen’s long-term strategy for the Asian market.
Model updates (20 May 2020)
- Prolia forecast adjusted lower due to impact from COVID-19
- AMG 510 forecast adjusted lower due to updated trial results presented at ASCO.
Model updates (4 March 2020)
- Mvasi forecast added due to Amgen providing brand-level revenue detail on biosimilars business
- Kanjinti forecast added due to Amgen providing brand-level revenue detail on biosimilars business
- Amgevita forecast added due to Amgen providing brand-level revenue detail on biosimilars business
- ABP 798 forecast added.
Model updates (21 November 2019)
- Otezla forecast added due to acquisition from Celgene.
Model updates (5 November 2019)
- Enbrel forecast adjusted higher due to US District Court of New Jersey ruling in favor of Amgen in its Enbrel litigation with Sandoz, extending patent protection until 2029
- Neulasta forecast adjusted higher in the near-term due to lower initial impact of biosimilar launches
- Evenity forecast adjusted higher due to continued Rest of World launches and continued growth in Japan
- Repatha forecast adjusted lower in the US due to continued pricing declines offsetting strong volume growth
- Kanjinti forecast adjusted in the US to align launch timing
- Mvasi forecast adjusted in the US to align launch timing.
Model updates (29 July 2019)
- Aimovig sales adjusted higher due to market share gains
- Repatha sales adjusted lower as pricing declines are offsetting strong unit volume growth
- Evenity sales adjusted higher due to strong launch in Japan
- Sensipar sales adjusted lower due to higher than expected initial impact of generic launches
- Tezepelumab forecast added
- Omecamtiv mecarbil forecast added
- AMG 510 forecast added.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
